Criminalization of drugs and drug users fuels HIV; laws should be reviewed, say experts

July 13, 2010

Strict laws on the criminalisation of drug use and drug users are fuelling the spread of HIV and other serious harms associated with the criminal market and should be reviewed, say experts in a series of articles published on bmj.com today to coincide with the 18th International AIDS Conference in Vienna, 18-23 July 2010.

Countries most affected include Russia and Ukraine, which operate strict drug laws and remain resistant to evidence-based harm reduction services like opiate substitution therapy and needle exchange programmes.

Professor Tim Rhodes and colleagues estimate that Russia could cut HIV rates by up to 55% if it legalised and scaled-up opiate substitution therapy and call for legal change to enable such treatment to tackle drug related harms.

Research shows that opioid substitution treatment can reduce risk of HIV infection by 60-84%, say Rhodes and colleagues. The World Health Organization promotes it as an "essential medicine" and methadone or buprenorphine substitutes are prescribed to over 650,000 people in Europe. Opioid substitution treatment is a core harm reduction intervention alongside distributing clean needles and providing easy access to HIV treatment.

Yet Russia prohibits opioid substitution treatment and has only about 75 needle and syringe programmes for its two million injecting drug users. It also has one of the fastest growing HIV epidemics in the world. A strong emphasis on the criminalisation of drug users hampers HIV prevention.

Using mathematical models, Rhodes and his team estimate that "Russia could substantially reduce the incidence of HIV infection if it permitted the use of opioid substitution treatment."

"The roots of resistance to harm reduction in Russia are complex," they add, "and show why efforts to bring about structural changes in national laws and policies should be at the forefront of global efforts to scale-up HIV prevention." The prohibition of opioid substitution treatment "limits rights of access to evidence-based health care, as championed by the UN and other international agencies."

In a second article, Stephen Rolles, Senior Policy Analyst at Transform Drug Policy Foundation argues that we need to end the criminalisation of drugs and instead set up regulatory models that will control drug markets and reduce the health and social harms caused by current policy.

He outlines Transform's blueprint for regulating drug availability and points to evidence that less punitive approaches do not necessarily lead to increased use. "Transform's blueprint does not seek to provide all the answers but to move the debate beyond whether we should end the war on drugs to what the world could look like after the war on drugs," he says. "It is a debate that the medical and public health sectors have failed to engage with for far too long."

In an accompanying feature, Richard Hurley of the BMJ reports on the situation in Ukraine, which has an estimated 290,000 drug injectors and possibly the highest prevalence of HIV in Europe. Despite entrenched corruption and police interference, he explores how community organisations are leading the fight against HIV among drug injectors and sex workers.

A linked study of injecting drug users in Edinburgh finds that while long term opiate substitution treatment reduces the risk of death, it does not reduce the overall duration of injecting. An editorial believes that doctors and scientists working in the field of drug addiction have an ethical obligation to speak out about the need for evidence based approaches to tackle drug related harms.

Finally a doctor and former heroin user gives a personal and candid account of his addiction. Writing anonymously, he says, "It has made me a better doctor, more understanding of human frailty because my own frailty is so stark."
-end-


BMJ

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.